November 16, 2016 - By Ellis Scott · 0 Comments
Immunocellular Therapeutics LTD (NYSEMKT:IMUC) institutional sentiment decreased to 1.25 in Q2 2016. Its down -1.08, from 2.33 in 2016Q1. The ratio fall, as 10 investment managers increased and opened new positions, while 8 decreased and sold stock positions in Immunocellular Therapeutics LTD. The investment managers in our partner’s database now own: 12.21 million shares, down from 12.23 million shares in 2016Q1. Also, the number of investment managers holding Immunocellular Therapeutics LTD in their top 10 positions was flat from 0 to 0 for the same number . Sold All: 2 Reduced: 6 Increased: 8 New Position: 2.
ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The company has a market cap of $9.48 million. The Firm is developing immune therapies for the treatment of cancers. It currently has negative earnings. The Company’s cancer immunotherapies target cancer stem cells , which are the drivers of tumor growth and disease recurrence.
About 2.72 million shares traded hands or 130.51% up from the average. ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) has declined 72.41% since April 14, 2016 and is downtrending. It has underperformed by 77.10% the S&P500.
According to Zacks Investment Research, “ImmunoCellular Therapeutics, Ltd. operates as a development stage company with primary focus on the development and commercialization of new therapeutics to fight cancer using the immune system. Its product candidate portfolio includes cellular immunotherapies targeting cancer and cancer stem cell antigens, peptide based immunotherapies targeting cancer stem cells, and monoclonal antibodies to diagnose and treat several different cancers. ImmunoCellular Therapeutics, Ltd. is based in California, USA.”
Bailard Inc. holds 0.06% of its portfolio in ImmunoCellular Therapeutics Ltd for 2.25 million shares. Sabby Management Llc owns 4.45 million shares or 0.05% of their US portfolio. Moreover, Bank Of America Corp De has 0% invested in the company for 1,085 shares. The New York-based Bank Of New York Mellon Corp has invested 0% in the stock. Barclays Plc, a United Kingdom-based fund reported 2,000 shares.#img1#
ImmunoCellular Therapeutics, Ltd., incorporated on March 20, 1987, is a clinical-stage biotechnology company. The Firm is developing immune therapies for the treatment of cancers. The Company’s cancer immunotherapies target cancer stem cells (CSCs), which are the drivers of tumor growth and disease recurrence. The Company’s product candidate is ICT-107, which is in phase III testing. In addition, the Company also has a portfolio of other potential therapeutic immunotherapies using a range of approaches to treat cancer. The Company’s other product candidates are ICT-140 for ovarian cancer and ICT-121 for recurrent glioblastoma multiforme (GBM).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Ellis Scott